Pulmonary Sarcoidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major pulmonary sarcoidosis markets reached a value of US$ 17.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 53.3 Billion by 2034, exhibiting a growth rate (CAGR) of 10.6% during 2024-2034.
The pulmonary sarcoidosis market has been comprehensively analyzed in IMARC's new report titled "Pulmonary Sarcoidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pulmonary sarcoidosis refers to a chronic systemic condition in which the immune system becomes overreactive, producing lumps or nodules called granulomas. The disorder most commonly affects the lungs and lymph nodes but can also impact any other organ. The general indications associated with pulmonary sarcoidosis include fatigue, swollen lymph nodes, fever, a feeling of discomfort or illness, shortness of breath, cough, pain and swelling in the joints, unexplained weight loss, night sweats, depression, etc. In severe cases, the ailment can lead to fibrosis, resulting in permanent lung scarring among patients. The diagnosis of this condition is difficult as the symptoms are common in many other diseases. A physical exam, several imaging procedures, such as CT scan, MRI, chest X-ray, etc., and a biopsy of suspicious granulomas are commonly used to diagnose pulmonary sarcoidosis. The healthcare provider may also perform endobronchial ultrasound-guided transbronchial fine needle aspiration to rule out other health problems.
The increasing prevalence of respiratory disorders caused by exposure to smoke, dust, chemicals, etc., is primarily driving the pulmonary sarcoidosis market. Apart from this, the rising incidences of bacterial and viral infections, which can trigger the immune system to respond actively, are also bolstering the market growth. Furthermore, the widespread adoption of anti-tumor necrosis factor-alpha antibodies and nonsteroidal anti-inflammatory drugs in disease treatment, since they reduce lung inflammation and boost overall health, is creating a positive outlook for the market. Besides this, the escalating utilization of immunosuppressants and corticosteroids, which work by modifying or suppressing the activity of the defense system and preventing disease progression, is also augmenting the market growth. Moreover, several key players are investing in R&D activities to innovate novel, cost-effective, and minimally invasive diagnostic tools that can aid in the early detection of disease among patients. This, in turn, is acting as another significant growth-inducing factor. Additionally, the ongoing development of subcutaneous human monoclonal antibodies, such as namilumab, that target granulocyte-macrophage colony-stimulating factors and provide quick symptom relief is expected to drive the pulmonary sarcoidosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the pulmonary sarcoidosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pulmonary sarcoidosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pulmonary sarcoidosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pulmonary sarcoidosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pulmonary sarcoidosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pulmonary sarcoidosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the pulmonary sarcoidosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pulmonary sarcoidosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pulmonary sarcoidosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of pulmonary sarcoidosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of pulmonary sarcoidosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pulmonary sarcoidosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with pulmonary sarcoidosis across the seven major markets?
What is the size of the pulmonary sarcoidosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pulmonary sarcoidosis?
What will be the growth rate of patients across the seven major markets?
Pulmonary Sarcoidosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pulmonary sarcoidosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pulmonary sarcoidosis market?
What are the key regulatory events related to the pulmonary sarcoidosis market?
What is the structure of clinical trial landscape by status related to the pulmonary sarcoidosis market?
What is the structure of clinical trial landscape by phase related to the pulmonary sarcoidosis market?
What is the structure of clinical trial landscape by route of administration related to the pulmonary sarcoidosis market?
The pulmonary sarcoidosis market has been comprehensively analyzed in IMARC's new report titled "Pulmonary Sarcoidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pulmonary sarcoidosis refers to a chronic systemic condition in which the immune system becomes overreactive, producing lumps or nodules called granulomas. The disorder most commonly affects the lungs and lymph nodes but can also impact any other organ. The general indications associated with pulmonary sarcoidosis include fatigue, swollen lymph nodes, fever, a feeling of discomfort or illness, shortness of breath, cough, pain and swelling in the joints, unexplained weight loss, night sweats, depression, etc. In severe cases, the ailment can lead to fibrosis, resulting in permanent lung scarring among patients. The diagnosis of this condition is difficult as the symptoms are common in many other diseases. A physical exam, several imaging procedures, such as CT scan, MRI, chest X-ray, etc., and a biopsy of suspicious granulomas are commonly used to diagnose pulmonary sarcoidosis. The healthcare provider may also perform endobronchial ultrasound-guided transbronchial fine needle aspiration to rule out other health problems.
The increasing prevalence of respiratory disorders caused by exposure to smoke, dust, chemicals, etc., is primarily driving the pulmonary sarcoidosis market. Apart from this, the rising incidences of bacterial and viral infections, which can trigger the immune system to respond actively, are also bolstering the market growth. Furthermore, the widespread adoption of anti-tumor necrosis factor-alpha antibodies and nonsteroidal anti-inflammatory drugs in disease treatment, since they reduce lung inflammation and boost overall health, is creating a positive outlook for the market. Besides this, the escalating utilization of immunosuppressants and corticosteroids, which work by modifying or suppressing the activity of the defense system and preventing disease progression, is also augmenting the market growth. Moreover, several key players are investing in R&D activities to innovate novel, cost-effective, and minimally invasive diagnostic tools that can aid in the early detection of disease among patients. This, in turn, is acting as another significant growth-inducing factor. Additionally, the ongoing development of subcutaneous human monoclonal antibodies, such as namilumab, that target granulocyte-macrophage colony-stimulating factors and provide quick symptom relief is expected to drive the pulmonary sarcoidosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the pulmonary sarcoidosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pulmonary sarcoidosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pulmonary sarcoidosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pulmonary sarcoidosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pulmonary sarcoidosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pulmonary sarcoidosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the pulmonary sarcoidosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pulmonary sarcoidosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pulmonary sarcoidosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of pulmonary sarcoidosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of pulmonary sarcoidosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pulmonary sarcoidosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with pulmonary sarcoidosis across the seven major markets?
What is the size of the pulmonary sarcoidosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pulmonary sarcoidosis?
What will be the growth rate of patients across the seven major markets?
Pulmonary Sarcoidosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pulmonary sarcoidosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pulmonary sarcoidosis market?
What are the key regulatory events related to the pulmonary sarcoidosis market?
What is the structure of clinical trial landscape by status related to the pulmonary sarcoidosis market?
What is the structure of clinical trial landscape by phase related to the pulmonary sarcoidosis market?
What is the structure of clinical trial landscape by route of administration related to the pulmonary sarcoidosis market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PULMONARY SARCOIDOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PULMONARY SARCOIDOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PULMONARY SARCOIDOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PULMONARY SARCOIDOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PULMONARY SARCOIDOSIS - UNMET NEEDS
10 PULMONARY SARCOIDOSIS - KEY ENDPOINTS OF TREATMENT
11 PULMONARY SARCOIDOSIS - MARKETED PRODUCTS
11.1 List of Pulmonary Sarcoidosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PULMONARY SARCOIDOSIS - PIPELINE DRUGS
12.1 List of Pulmonary Sarcoidosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Efzofitimod - aTyr Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CMK 389 - Novartis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Namilumab - Kinevant Sciences GmbH
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 RLF 100 - Relief Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PULMONARY SARCOIDOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PULMONARY SARCOIDOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PULMONARY SARCOIDOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pulmonary Sarcoidosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pulmonary Sarcoidosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pulmonary Sarcoidosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pulmonary Sarcoidosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pulmonary Sarcoidosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pulmonary Sarcoidosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pulmonary Sarcoidosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pulmonary Sarcoidosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
16 PULMONARY SARCOIDOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PULMONARY SARCOIDOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PULMONARY SARCOIDOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PULMONARY SARCOIDOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PULMONARY SARCOIDOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PULMONARY SARCOIDOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PULMONARY SARCOIDOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PULMONARY SARCOIDOSIS - UNMET NEEDS
10 PULMONARY SARCOIDOSIS - KEY ENDPOINTS OF TREATMENT
11 PULMONARY SARCOIDOSIS - MARKETED PRODUCTS
11.1 List of Pulmonary Sarcoidosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PULMONARY SARCOIDOSIS - PIPELINE DRUGS
12.1 List of Pulmonary Sarcoidosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Efzofitimod - aTyr Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CMK 389 - Novartis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Namilumab - Kinevant Sciences GmbH
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 RLF 100 - Relief Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PULMONARY SARCOIDOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PULMONARY SARCOIDOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PULMONARY SARCOIDOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pulmonary Sarcoidosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pulmonary Sarcoidosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pulmonary Sarcoidosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pulmonary Sarcoidosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pulmonary Sarcoidosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pulmonary Sarcoidosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pulmonary Sarcoidosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pulmonary Sarcoidosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pulmonary Sarcoidosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
16 PULMONARY SARCOIDOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PULMONARY SARCOIDOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PULMONARY SARCOIDOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
